This finding suggests that the generation of tumor-specific CD8+ T cells combined with TME remodeling constitutes a promising strategy for driving the success of tumor immunotherapy.348 However, the lack of sustainable immune activity post-vaccination limits its long-term efficacy. This evidence concerns the gene CD8A and neoplasm.